Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Shao, Zhimin"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 32
Tytuł:
Adjuvant medial versus entire supraclavicular lymph node irradiation in high-risk early breast cancer (SUCLANODE): a protocol for a multicenter, randomized, open-label, phase 3 trial.
Autorzy:
Zhang L; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Mei X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Hu Z; Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
Yu B; Department of Radiotherapy, the Affiliated Jiangyin Hospital of Nantong University, Jiangyin, 214400, China.
Zhang C; Department of Radiation Oncology, The First Hospital of Quanzhou Affiliated to Fujian Medical University, Fuzhou, China.
Li Y; Department of Oncology, Guizhou Provincial People's Hospital, Guiyang, China.
Liu K; Department of Radiation Oncology, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang, 315040, China.
Ma X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Ma J; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Chen X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Meng J; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Shi W; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Wang X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Mo M; Department of Cancer Prevention & Clinical Statistics Center, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Shao Z; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Zhang Z; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Yu X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Guo X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China. .; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. .; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China. .
Yang Z; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China. .; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. .; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China. .; Department of Medical Oncology, Kashgar Prefecture Second People ' s Hospital, Xinjiang Uyghur Autonomous Region, Kashgar, 844000, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Jan 09; Vol. 24 (1), pp. 49. Date of Electronic Publication: 2024 Jan 09.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Breast Neoplasms*/radiotherapy
Breast Neoplasms*/surgery
Humans ; Female ; Mastectomy ; Adjuvants, Immunologic ; Lymph Nodes ; Breast ; Randomized Controlled Trials as Topic ; Multicenter Studies as Topic ; Clinical Trials, Phase III as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Favorable prognosis of breast cancer brain metastases patients with limited intracranial and extracranial metastatic lesions.
Autorzy:
Shi W; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Li Y; Affiliated Hospital of Jining Medical University, Jining, 272029, Shandong, China.
Sun H; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Zhang L; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Meng J; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Wang X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Chen X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Zhang X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Mei X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Ma J; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Mo M; Department of Cancer Prevention and Clinical Statistics Center, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Zhou C; Department of Cancer Prevention and Clinical Statistics Center, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Liang F; Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, China.
Shao Z; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Zhang Z; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Guo X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
Yu X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China. .; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. .; Shanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China. .
Yang Z; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China. .; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. .; Shanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China. .
Pokaż więcej
Źródło:
Radiation oncology (London, England) [Radiat Oncol] 2023 Jul 01; Vol. 18 (1), pp. 107. Date of Electronic Publication: 2023 Jul 01.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/therapy
Brain Neoplasms*/therapy
Humans ; Female ; Prognosis ; Breast ; Salvage Therapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Molecular subtypes predict second breast events of ductal carcinoma in situ after breast-conserving surgery.
Autorzy:
Yang Y; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.
Zhao X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.
Wang X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.
Jin K; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.
Luo J; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.
Yang Z; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.
Mei X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.
Ma J; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.
Shao Z; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhang Z; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.
Chen X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.
Guo X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.
Yu X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2022 Jul; Vol. 11 (14), pp. 2755-2766. Date of Electronic Publication: 2022 May 22.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Breast Neoplasms*
Carcinoma, Intraductal, Noninfiltrating*/pathology
Triple Negative Breast Neoplasms*/genetics
Triple Negative Breast Neoplasms*/surgery
Female ; Humans ; Mastectomy, Segmental ; Prognosis ; Receptor, ErbB-2/metabolism ; Receptors, Progesterone/metabolism ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Integration of radiogenomic features for early prediction of pathological complete response in patients with triple-negative breast cancer and identification of potential therapeutic targets.
Autorzy:
Zhang Y; Department of Breast Surgery, Fudan University Shanghai Cancer Center, 270 Dongan Road, Xuhui District, Shanghai, People's Republic of China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
You C; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.; Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Pei Y; Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Yang F; Department of Breast Surgery, Fudan University Shanghai Cancer Center, 270 Dongan Road, Xuhui District, Shanghai, People's Republic of China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Li D; Department of Breast Surgery, Fudan University Shanghai Cancer Center, 270 Dongan Road, Xuhui District, Shanghai, People's Republic of China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Jiang YZ; Department of Breast Surgery, Fudan University Shanghai Cancer Center, 270 Dongan Road, Xuhui District, Shanghai, People's Republic of China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Shao Z; Department of Breast Surgery, Fudan University Shanghai Cancer Center, 270 Dongan Road, Xuhui District, Shanghai, People's Republic of China. .; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2022 Jun 07; Vol. 20 (1), pp. 256. Date of Electronic Publication: 2022 Jun 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Breast Neoplasms*
Triple Negative Breast Neoplasms*/diagnostic imaging
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/genetics
Epirubicin/therapeutic use ; Female ; Humans ; Magnetic Resonance Imaging/methods ; Neoadjuvant Therapy ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Postoperative radiotherapy improves overall survival in patients with primary squamous cell carcinoma of the breast.
Autorzy:
Wang X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China.
Zhang L; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China.
Luo J; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China.
Jin K; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China.
Yang Z; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China.
Meng J; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China.
Zhang X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China.
Zhang Z; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China.
Shao Z; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China.; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China.
Guo X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China.
Chen X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China.
Yu X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China.
Pokaż więcej
Źródło:
Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2021 Dec; Vol. 17 (6), pp. 454-461. Date of Electronic Publication: 2020 Oct 20.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/radiotherapy
Breast Neoplasms*/surgery
Carcinoma, Squamous Cell*/pathology
Carcinoma, Squamous Cell*/radiotherapy
Carcinoma, Squamous Cell*/surgery
Female ; Humans ; Neoplasm Staging ; Prognosis ; Retrospective Studies ; SEER Program
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy.
Autorzy:
Chen S; Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Han Y; Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Ouyang Q; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, Changsha, Hunan, China.
Lu J; Department of General Surgery, Xi'an Tangdu Hospital, Xi'an, Shanxi, China.
Zhang Q; Department of Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Yang S; Department of Breast Cancer and Lymphoma, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Wang J; Department of Internal Medicine, Linyi Tumor Hospital, Linyi, Shandong, China.
Huang H; Department of Oncology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China.
Liu H; Department of Breast Surgery, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Shao Z; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Li H; Department of Breast Surgery, Sichuan Province Tumor Hospital, Chengdu, Sichuan, China.
Chen Z; Department of Medical Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Sun S; Department of Medical Oncology, Central Hospital of Xuzhou, the Cancer Institute of Southeast University, Xuzhou, Jiangsu, China.
Geng C; First Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Lu J; Department of Medical Oncology, Nantong Tumor Hospital, Nantong, Jiangsu, China.
Sun J; Department of Tumor, Yunnan First People's Hospital, Kunming, Yunnan, China.
Wang J; Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China. .
Xu B; Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2021 Mar 31; Vol. 21 (1), pp. 341. Date of Electronic Publication: 2021 Mar 31.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Anthracyclines/*therapeutic use
Breast Neoplasms/*drug therapy
Granulocyte Colony-Stimulating Factor/*metabolism
Serum Albumin/*metabolism
Female ; Humans ; Middle Aged ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Outcomes and risk of subsequent breast events in breast-conserving surgery patients with BRCA1 and BRCA2 mutation.
Autorzy:
Ye F; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Huang L; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Lang G; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Hu X; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Di G; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Shao Z; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.; Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Cao A; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2020 Mar; Vol. 9 (5), pp. 1903-1910. Date of Electronic Publication: 2020 Jan 07.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms/*surgery
Carcinoma, Ductal, Breast/*surgery
Mastectomy, Segmental/*statistics & numerical data
Neoplasm Recurrence, Local/*epidemiology
Adult ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Breast/pathology ; Breast/surgery ; Breast Neoplasms/genetics ; Breast Neoplasms/mortality ; Carcinoma, Ductal, Breast/genetics ; Carcinoma, Ductal, Breast/mortality ; China/epidemiology ; Clinical Decision-Making ; Disease-Free Survival ; Female ; Genetic Predisposition to Disease ; Germ-Line Mutation ; Heterozygote ; Humans ; Mastectomy, Segmental/standards ; Middle Aged ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/prevention & control ; Practice Guidelines as Topic ; Prognosis ; Prophylactic Mastectomy/standards ; Retrospective Studies ; Risk Assessment/statistics & numerical data ; Risk Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review.
Autorzy:
Li J; Department of Surgery in Breast Cancer, Fudan University Shanghai Cancer Center, Shanghai, China.
Wang Z; Department of Surgery in Breast Cancer, Fudan University Shanghai Cancer Center, Shanghai, China.
Shao Z; Department of Surgery in Breast Cancer, Fudan University Shanghai Cancer Center, Shanghai, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2019 May; Vol. 8 (5), pp. 1943-1957. Date of Electronic Publication: 2019 Apr 19.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents, Hormonal/*therapeutic use
Breast Neoplasms/*drug therapy
Fulvestrant/*therapeutic use
Animals ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers ; Humans ; Prognosis ; Receptor, ErbB-2 ; Receptors, Estrogen ; Receptors, Progesterone
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Mammographic density and other risk factors for breast cancer among women in China.
Autorzy:
Li T; Medical Radiation Sciences, Faculty of Health Sciences, The University of Sydney, Lidcombe, NSW, Australia.
Tang L; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.
Gandomkar Z; Medical Radiation Sciences, Faculty of Health Sciences, The University of Sydney, Lidcombe, NSW, Australia.
Heard R; Behaviour and Social Sciences in Health, Faculty of Health Sciences, The University of Sydney, Lidcombe, NSW, Australia.
Mello-Thoms C; Medical Radiation Sciences, Faculty of Health Sciences, The University of Sydney, Lidcombe, NSW, Australia.
Shao Z; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.
Brennan P; Medical Radiation Sciences, Faculty of Health Sciences, The University of Sydney, Lidcombe, NSW, Australia.
Pokaż więcej
Źródło:
The breast journal [Breast J] 2018 May; Vol. 24 (3), pp. 426-428. Date of Electronic Publication: 2017 Nov 29.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Density*
Breast Neoplasms/*diagnostic imaging
Breast Neoplasms/*etiology
Adult ; Aged ; Asian People ; Body Mass Index ; China ; Female ; Humans ; Logistic Models ; Mammography ; Middle Aged ; Reproductive History ; Risk Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo.
Autorzy:
Jia X; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China.
Cheng J; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.
Shen Z; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China.
Shao Z; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China.
Liu G; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China.
Pokaż więcej
Źródło:
Molecular medicine reports [Mol Med Rep] 2018 Apr; Vol. 17 (4), pp. 5470-5476. Date of Electronic Publication: 2018 Jan 29.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms/*metabolism
Diphosphonates/*pharmacology
Estradiol/*analogs & derivatives
Extracellular Signal-Regulated MAP Kinases/*metabolism
Hypoxia-Inducible Factor 1/*metabolism
Imidazoles/*pharmacology
Signal Transduction/*drug effects
Animals ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Cell Line, Tumor ; Disease Models, Animal ; Drug Synergism ; Estradiol/pharmacology ; Female ; Fulvestrant ; Gene Expression ; Humans ; Hypoxia-Inducible Factor 1/genetics ; Hypoxia-Inducible Factor 1, alpha Subunit/genetics ; Hypoxia-Inducible Factor 1, alpha Subunit/metabolism ; Mice ; Models, Biological ; Xenograft Model Antitumor Assays ; Zoledronic Acid
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Quality of Life and Psychological State in Chinese Breast Cancer Patients Who Received BRCA1/2 Genetic Testing.
Autorzy:
Qiu J; Department of Nursing Administration, Shanghai Cancer Center, Fudan University, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Guan J; Department of Nursing Administration, Shanghai Cancer Center, Fudan University, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yang X; Department of Breast Surgery, Shanghai Cancer Center, Fudan University, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Wu J; Department of Breast Surgery, Shanghai Cancer Center, Fudan University, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Liu G; Department of Breast Surgery, Shanghai Cancer Center, Fudan University, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Di G; Department of Breast Surgery, Shanghai Cancer Center, Fudan University, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Chen C; Department of Breast Surgery, Shanghai Cancer Center, Fudan University, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Hou Y; Department of Breast Surgery, Shanghai Cancer Center, Fudan University, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Han Q; Department of Breast Surgery, Shanghai Cancer Center, Fudan University, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Shen Z; Department of Breast Surgery, Shanghai Cancer Center, Fudan University, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Shao Z; Department of Breast Surgery, Shanghai Cancer Center, Fudan University, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Hu Z; Department of Breast Surgery, Shanghai Cancer Center, Fudan University, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2016 Jul 18; Vol. 11 (7), pp. e0158531. Date of Electronic Publication: 2016 Jul 18 (Print Publication: 2016).
Typ publikacji:
Journal Article
MeSH Terms:
Quality of Life*
BRCA1 Protein/*genetics
BRCA2 Protein/*genetics
Breast Neoplasms/*genetics
Adult ; Aged ; Asian People/genetics ; Breast/metabolism ; Breast/pathology ; Breast Neoplasms/diagnosis ; Breast Neoplasms/epidemiology ; Breast Neoplasms/psychology ; China/epidemiology ; Female ; Genes, BRCA1 ; Genetic Testing ; Humans ; Middle Aged ; Mutation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Breast Cancer-Specific Mortality Pattern and Its Changing Feature According to Estrogen Receptor Status in Two Time Periods.
Autorzy:
Li J; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Liu Y; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Jiang Y; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Shao Z; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2016 Jun 14; Vol. 11 (6), pp. e0157322. Date of Electronic Publication: 2016 Jun 14 (Print Publication: 2016).
Typ publikacji:
Journal Article
MeSH Terms:
Breast/*pathology
Breast Neoplasms/*diagnosis
Breast Neoplasms/*epidemiology
Receptors, Estrogen/*analysis
Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms/mortality ; Cohort Studies ; Female ; Humans ; Middle Aged ; Proportional Hazards Models ; SEER Program ; Survival Analysis ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study.
Autorzy:
Cao A; Department of Breast Surgery, Fudan University Shanghai Cancer Center, No. 270 Dongan Road, Xuhui District, Shanghai, 200032, China.
Zhang J; Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Liu X; Department of Breast Surgery, Jiangsu Province Hospital, Nanjing, China.
Wu W; Department of Oncology Surgery, Ningbo Medical Treatment Center Lihuili Hospital, Ningbo, 315000, China.
Liu Y; Breast Disease Center, Peking University First Hospital, Beijing, 100034, China.
Fan Z; Department of Breast Surgery, First Hospital of Jilin University, Changchun, 130021, China.
Zhang A; Breast Disease Center, Guangdong Women and Children's Hospital and Health Institute, Guangzhou, 510010, China.
Zhou T; Department of Breast Disease, Yunnan Tumor Hospital, Kunming, 650118, China.
Fu P; Breast Disease Center, First Affiliated Hospital of Medicine College of Zhejiang University, Hangzhou, 310006, China.
Wang S; Breast Disease Center, Peking University People's Hospital, Beijing, 100044, China.
Ouyang Q; Medical Oncology Center, Hunan Tumor Hospital, Changsha, 410000, China.
Tang J; Department of General Surgery, Jiangsu Cancer Hospital, Nanjing, 210009, China.
Jiang H; Department of General Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
Zhang X; Department of Oncology Surgery, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, 325000, China.
Pang D; Department of Breast Surgery, The Tumor Hospital of Harbin Medical University, Harbin, 150040, China.
He J; Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, 710000, China.
Shi L; Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, Shanghai, 200072, China.
Wang X; Department of Breast and Thyroid Surgery, Shenzhen Second Hospital, Shenzhen, 518000, China.
Sheng Y; Department of Breast Surgery, Shanghai Changhai Hospital, Shanghai, 200433, China.
Mao D; Department of Breast Surgery, The Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou, 550004, China.
Shao Z; Department of Breast Surgery, Fudan University Shanghai Cancer Center, No. 270 Dongan Road, Xuhui District, Shanghai, 200032, China. .
Pokaż więcej
Źródło:
Health and quality of life outcomes [Health Qual Life Outcomes] 2016 Mar 24; Vol. 14, pp. 51. Date of Electronic Publication: 2016 Mar 24.
Typ publikacji:
Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Quality of Life*
Antineoplastic Agents/*therapeutic use
Aromatase Inhibitors/*therapeutic use
Breast Neoplasms/*drug therapy
Breast Neoplasms/*physiopathology
Postmenopause/*physiology
Aged ; Asian People ; China ; Drug Therapy, Combination ; Female ; Humans ; Middle Aged ; Prospective Studies ; Time Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Molecular portrait of breast cancer in China reveals comprehensive transcriptomic likeness to Caucasian breast cancer and low prevalence of luminal A subtype.
Autorzy:
Huang X; Department of Breast Surgery, Fudan University Shanghai Cancer Center and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Dugo M; Functional Genomics and Bioinformatics, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Callari M; Biomarkers Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Sandri M; Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
De Cecco L; Functional Genomics and Bioinformatics, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Valeri B; Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Carcangiu ML; Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Xue J; Department of Breast Surgery, Fudan University Shanghai Cancer Center and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Bi R; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Veneroni S; Biomarkers Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Daidone MG; Biomarkers Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Ménard S; Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Tagliabue E; Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Shao Z; Department of Breast Surgery, Fudan University Shanghai Cancer Center and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Wu J; Department of Breast Surgery, Fudan University Shanghai Cancer Center and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Orlandi R; Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2015 Jul; Vol. 4 (7), pp. 1016-30. Date of Electronic Publication: 2015 Mar 18.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Asian People*
Transcriptome*
White People*
Breast Neoplasms/*genetics
Breast Neoplasms/*pathology
Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor ; Breast Neoplasms/epidemiology ; Cluster Analysis ; Extracellular Matrix/genetics ; Female ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Humans ; MicroRNAs/genetics ; Middle Aged ; Neoplasm Grading ; Prevalence ; Tumor Burden
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
In-line phase-contrast and grating-based phase-contrast synchrotron imaging study of brain micrometastasis of breast cancer.
Autorzy:
Huang S; Department of Breast Surgery, Breast Cancer Institute, Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Kou B; Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Chi Y; Department of Breast Surgery, Breast Cancer Institute, Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Xi Y; 1] School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, People's Republic of China [2] Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Cao Y; Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Cui W; 1] Department of Pathology, Fudan University, Shanghai Cancer Center, Shanghai, People's Republic of China [2] Department of Pathology, First Affiliated Hospital Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
Hu X; Department of Breast Surgery, Breast Cancer Institute, Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Shao Z; Department of Breast Surgery, Breast Cancer Institute, Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Guo H; Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, People's Republic of China.
Fu Y; Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, People's Republic of China.
Xiao T; Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, People's Republic of China.
Sun J; School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Zhao J; 1] School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, People's Republic of China [2] Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Wang Y; Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Wu J; Department of Breast Surgery, Breast Cancer Institute, Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2015 Mar 30; Vol. 5, pp. 9418. Date of Electronic Publication: 2015 Mar 30.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Diagnostic Imaging*
Brain Neoplasms/*diagnostic imaging
Breast Neoplasms/*diagnostic imaging
Neoplasm Micrometastasis/*diagnostic imaging
Animals ; Brain Neoplasms/pathology ; Brain Neoplasms/secondary ; Breast Neoplasms/pathology ; Contrast Media/administration & dosage ; Female ; Humans ; Mice ; Neoplasm Micrometastasis/pathology ; Radiography ; Synchrotrons
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Phase II study of Pseudomonas aeruginosa-Mannose-Sensitive hemagglutinin in combination with capecitabine for Her-2-negative metastatic breast cancer pretreated with anthracycline and taxane.
Autorzy:
Lv F; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Cao J; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Liu Z; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Wang Z; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Zhang J; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Zhang S; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Wang L; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Zhao X; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Shao Z; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Wang B; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Hu X; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2015 Mar 13; Vol. 10 (3), pp. e0118607. Date of Electronic Publication: 2015 Mar 13 (Print Publication: 2015).
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*pharmacology
Breast Neoplasms/*therapy
Capecitabine/*pharmacology
Hemagglutinins/*immunology
Mannose/*pharmacology
Pseudomonas aeruginosa/*physiology
Receptor, ErbB-2/*deficiency
Adolescent ; Adult ; Aged ; Anthracyclines/pharmacology ; Breast Neoplasms/drug therapy ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Bridged-Ring Compounds/pharmacology ; Capecitabine/therapeutic use ; Female ; Humans ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Metastasis ; Pseudomonas aeruginosa/drug effects ; Pseudomonas aeruginosa/genetics ; Safety ; Salvage Therapy ; Taxoids/pharmacology ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Similar prognoses for invasive micropapillary breast carcinoma and pure invasive ductal carcinoma: a retrospectively matched cohort study in China.
Autorzy:
Liu Y; Department of Breast Surgery, Fudan University Shanghai Cancer Center/Cancer Institute, Shanghai, People's Republic of China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Huang X; Department of Breast Surgery, Fudan University Shanghai Cancer Center/Cancer Institute, Shanghai, People's Republic of China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Bi R; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; Department of Pathology, Fudan University Shanghai Cancer Center/Cancer Institute, Shanghai, People's Republic of China.
Yang W; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; Department of Pathology, Fudan University Shanghai Cancer Center/Cancer Institute, Shanghai, People's Republic of China.
Shao Z; Department of Breast Surgery, Fudan University Shanghai Cancer Center/Cancer Institute, Shanghai, People's Republic of China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; Institutes of Biomedical Science, Fudan University, Shanghai, People's Republic of China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2014 Sep 04; Vol. 9 (9), pp. e106564. Date of Electronic Publication: 2014 Sep 04 (Print Publication: 2014).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Breast Neoplasms/*pathology
Carcinoma, Ductal, Breast/*pathology
Adult ; Aged ; Aged, 80 and over ; China ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The role of mammographic calcification in the neoadjuvant therapy of breast cancer imaging evaluation.
Autorzy:
Li JJ; Department of Breast Surgery, Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, China.
Chen C; Department of Breast Surgery, Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, China.
Gu Y; Department of Diagnostic Radiology, Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, China.
Di G; Department of Breast Surgery, Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, China.
Wu J; Department of Breast Surgery, Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, China.
Liu G; Department of Breast Surgery, Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, China.
Shao Z; Department of Breast Surgery, Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2014 Feb 11; Vol. 9 (2), pp. e88853. Date of Electronic Publication: 2014 Feb 11 (Print Publication: 2014).
Typ publikacji:
Clinical Trial, Phase II; Journal Article
MeSH Terms:
Breast Neoplasms/*diagnostic imaging
Breast Neoplasms/*therapy
Mammography/*methods
Antineoplastic Agents/therapeutic use ; Biomarkers/metabolism ; Calcinosis/metabolism ; Decision Making ; Estrogen Receptor alpha/metabolism ; Female ; Humans ; In Situ Hybridization, Fluorescence ; Neoadjuvant Therapy ; Prospective Studies ; Receptors, Progesterone/metabolism ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis.
Autorzy:
Jiang Y; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Yin W
Zhou L
Yan T
Zhou Q
Du Y
Shen Z
Shao Z
Lu J
Pokaż więcej
Źródło:
PloS one [PLoS One] 2012; Vol. 7 (3), pp. e32474. Date of Electronic Publication: 2012 Mar 02.
Typ publikacji:
Journal Article; Meta-Analysis
MeSH Terms:
Anthracyclines/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Breast Neoplasms/*drug therapy
Deoxycytidine/*analogs & derivatives
Fluorouracil/*analogs & derivatives
Taxoids/*therapeutic use
Capecitabine ; Chemotherapy, Adjuvant ; Data Interpretation, Statistical ; Deoxycytidine/therapeutic use ; Disease-Free Survival ; Female ; Fluorouracil/therapeutic use ; Humans ; Proportional Hazards Models ; Randomized Controlled Trials as Topic ; Receptor, ErbB-2/metabolism ; Salvage Therapy/methods ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.
Autorzy:
Wang L; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Zhang Q
Zhang J
Sun S
Guo H
Jia Z
Wang B
Shao Z
Wang Z
Hu X
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2011 Jun 15; Vol. 11, pp. 248. Date of Electronic Publication: 2011 Jun 15.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal/*pharmacology
Breast Neoplasms/*enzymology
Drug Resistance, Neoplasm/*physiology
Neoplasm Proteins/*physiology
Phosphatidylinositol 3-Kinases/*physiology
Quinazolines/*pharmacology
Adult ; Aged ; Anthracyclines/administration & dosage ; Antibiotics, Antineoplastic/administration & dosage ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Capecitabine ; Class I Phosphatidylinositol 3-Kinases ; DNA Mutational Analysis ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Disease-Free Survival ; Enzyme Activation/genetics ; Exons/genetics ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/analogs & derivatives ; Follow-Up Studies ; Genes, erbB-2 ; Humans ; Lapatinib ; Middle Aged ; Mutation ; Neoplasm Proteins/analysis ; Neoplasm Proteins/genetics ; PTEN Phosphohydrolase/analysis ; Phosphatidylinositol 3-Kinases/genetics ; Quinazolines/administration & dosage ; Taxoids/administration & dosage ; Trastuzumab ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 32

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies